5 Literaturverzeichnis
18. van der Horst-Bruinsma IE, Zack DJ, Szumski A, Koenig AS. Female patients with ankylosing spondylitis: analysis of the impact of gender across treatment studies. Ann Rheum Dis 2013,72:1221-1224.
19. Resnick D, Dwosh IL, Goergen TG, Shapiro RF, D'Ambrosia R. Clinical and radiographic "reankylosis" following hip surgery in ankylosing spondylitis. AJR Am J Roentgenol 1976,126:1181-1188.
20. Boonen A, van der Linden SM. The burden of ankylosing spondylitis. J Rheumatol Suppl 2006,78:4-11.
21. Little H, Swinson DR, Cruickshank B. Upward subluxation of the axis in ankylosing spondylitis. A clinical pathologic report. Am J Med 1976,60:279-285.
22. Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis 2002,61 Suppl 3:iii8-18.
23. Ward MM, Kuzis S. Risk factors for work disability in patients with ankylosing spondylitis. J Rheumatol 2001,28:315-321.
24. Calin A, Porta J, Fries JF, Schurman DJ. Clinical history as a screening test for ankylosing spondylitis. JAMA 1977,237:2613-2614.
25. Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum 2005,52:1000-1008.
26. Haibel H, Rudwaleit M, Sieper J. [Outcome parameters in ankylosing spondylitis]. Z Rheumatol 2006,65:131-134, 136-138.
27. Poddubnyy D, Gaydukova I, Hermann KG, Song IH, Haibel H, Braun J, et al.
Magnetic resonance imaging compared to conventional radiographs for detection of chronic structural changes in sacroiliac joints in axial spondyloarthritis. J Rheumatol 2013,40:1557-1565.
28. Braun J, Rudwaleit M, Hermann KG, Rau R. [Imaging in ankylosing spondylitis]. Z Rheumatol 2007,66:167-178.
29. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC, Jr., Dijkmans B, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006,65:442-452.
30. Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011,70:896-904.
31. Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Marker-Hermann E, Zeidler H, et al.
Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 2012,71:1616-1622.
32. Chen J, Veras MM, Liu C, Lin J. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2013,2:CD004524.
33. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al.
Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005,52:582-591.
34. Davis JC, Jr., Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al.
Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003,48:3230-3236.
35. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al.
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006,54:2136-2146.
5 Literaturverzeichnis
36. Inman RD, Davis JC, Jr., Heijde D, Diekman L, Sieper J, Kim SI, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008,58:3402-3412.
37. Haibel H, Rudwaleit M, Listing J, Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 2005,64:296-298.
38. Song IH, Heldmann F, Rudwaleit M, Haibel H, Weiss A, Braun J, et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 2011,70:1108-1110.
39. Sieper J, Porter-Brown B, Thompson L, Harari O, Dougados M. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis 2014,73:95-100.
40. Sieper J, Braun J, Kay J, Badalamenti S, Radin AR, Jiao L, et al. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis 2014.
41. Appel H, Maier R, Wu P, Scheer R, Hempfing A, Kayser R, et al. Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther 2011,13:R95.
42. Appel H, Maier R, Bleil J, Hempfing A, Loddenkemper C, Schlichting U, et al. In situ analysis of interleukin-23- and interleukin-12-positive cells in the spine of patients with ankylosing spondylitis. Arthritis Rheum 2013,65:1522-1529.
43. Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 2013,382:1705-1713.
44. Poddubnyy D, Hermann KG, Callhoff J, Listing J, Sieper J. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis 2014,73:817-823.
45. Ziwjan JL. [The treatment of flexion deformities of the spine in Bechterew disease].
Beitr Orthop Traumatol 1982,29:195-199.
46. Hehne HJ, Zielke K, Bohm H. Polysegmental lumbar osteotomies and transpedicled fixation for correction of long-curved kyphotic deformities in ankylosing spondylitis.
Report on 177 cases. Clin Orthop Relat Res 1990:49-55.
47. Van Royen BJ, De Gast A. Lumbar osteotomy for correction of thoracolumbar kyphotic deformity in ankylosing spondylitis. A structured review of three methods of treatment. Ann Rheum Dis 1999,58:399-406.
48. Weber U, Maksymowych WP. Advances and challenges in spondyloarthritis imaging for diagnosis and assessment of disease. Curr Rheumatol Rep 2013,15:345.
49. Tsui FW, Tsui HW, Akram A, Haroon N, Inman RD. The genetic basis of ankylosing spondylitis: new insights into disease pathogenesis. Appl Clin Genet 2014,7:105-115.
50. Brown MA, Kennedy LG, MacGregor AJ, Darke C, Duncan E, Shatford JL, et al.
Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum 1997,40:1823-1828.
51. Hermann E, Yu DT, Meyer zum Buschenfelde KH, Fleischer B. HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet 1993,342:646-650.
52. Atagunduz P, Appel H, Kuon W, Wu P, Thiel A, Kloetzel PM, et al. HLA-B27-restricted CD8+ T cell response to cartilage-derived self peptides in ankylosing spondylitis. Arthritis Rheum 2005,52:892-901.
5 Literaturverzeichnis
53. Kollnberger S, Bird LA, Roddis M, Hacquard-Bouder C, Kubagawa H, Bodmer HC, et al. HLA-B27 heavy chain homodimers are expressed in HLA-B27 transgenic rodent models of spondyloarthritis and are ligands for paired Ig-like receptors. J Immunol 2004,173:1699-1710.
54. Colbert RA, Tran TM, Layh-Schmitt G. HLA-B27 misfolding and ankylosing spondylitis. Mol Immunol 2014,57:44-51.
55. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med 2006,3:e297.
56. Taurog JD, Maika SD, Satumtira N, Dorris ML, McLean IL, Yanagisawa H, et al.
Inflammatory disease in HLA-B27 transgenic rats. Immunol Rev 1999,169:209-223.
57. Tran TM, Dorris ML, Satumtira N, Richardson JA, Hammer RE, Shang J, et al.
Additional human beta2-microglobulin curbs HLA-B27 misfolding and promotes arthritis and spondylitis without colitis in male HLA-B27-transgenic rats. Arthritis Rheum 2006,54:1317-1327.
58. May E, Dorris ML, Satumtira N, Iqbal I, Rehman MI, Lightfoot E, et al. CD8 alpha beta T cells are not essential to the pathogenesis of arthritis or colitis in HLA-B27 transgenic rats. J Immunol 2003,170:1099-1105.
59. Wollenhaupt HJ, Schneider C, Zeidler H, Krech T, Kuntz BM. [Clinical and serological characterization of Chlamydia-induced arthritis]. Dtsch Med Wochenschr 1989,114:1949-1954.
60. Granfors K, Jalkanen S, von Essen R, Lahesmaa-Rantala R, Isomaki O, Pekkola-Heino K, et al. Yersinia antigens in synovial-fluid cells from patients with reactive arthritis. N Engl J Med 1989,320:216-221.
61. Leirisalo-Repo M, Helenius P, Hannu T, Lehtinen A, Kreula J, Taavitsainen M, et al.
Long-term prognosis of reactive salmonella arthritis. Ann Rheum Dis 1997,56:516-520.
62. May E, Marker-Hermann E, Wittig BM, Zeitz M, Meyer zum Buschenfelde KH, Duchmann R. Identical T-cell expansions in the colon mucosa and the synovium of a patient with enterogenic spondyloarthropathy. Gastroenterology 2000,119:1745-1755.
63. Vasey FB, Deitz C, Fenske NA, Germain BF, Espinoza LR. Possible involvement of group A streptococci in the pathogenesis of psoriatic arthritis. J Rheumatol 1982,9:719-722.
64. Purrmann J, Bertrams J, Munch H, Zeidler H, Juli E, Reis HE, et al. [HLA association of seronegative spondylarthritis in patients with Crohn disease]. Med Klin (Munich) 1987,82:560-563.
65. De Vos M, Cuvelier C, Mielants H, Veys E, Barbier F, Elewaut A. Ileocolonoscopy in seronegative spondylarthropathy. Gastroenterology 1989,96:339-344.
66. Lange U, Berliner M, Weidner W, Schiefer HG, Schmidt KL, Federlin K. [Ankylosing spondylitis and urogenital infection: diagnosis of urologic infection and correlation with rheumatologic findings]. Z Rheumatol 1996,55:249-255.
67. Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernandez-Sueiro JL, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994,180:2359-2364.
68. von Muhlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 1995,24:323-358.
69. Dorner T, Egerer K, Feist E, Burmester GR. Rheumatoid factor revisited. Curr Opin Rheumatol 2004,16:246-253.
70. Rosenberg JN, Johnson GD, Holborow EJ. Antinuclear antibodies in ankylosing spondylitis, psoriatic arthritis, and psoriasis. Ann Rheum Dis 1979,38:526-528.
5 Literaturverzeichnis
71. Baerlecken NT, Nothdorft S, Stummvoll GH, Sieper J, Rudwaleit M, Reuter S, et al.
Autoantibodies against CD74 in spondyloarthritis. Ann Rheum Dis 2014,73:1211-1214.
72. Mort JS, Billington CJ. Articular cartilage and changes in arthritis: matrix degradation.
Arthritis Res 2001,3:337-341.
73. Maciewicz RA, Wotton SF, Etherington DJ, Duance VC. Susceptibility of the cartilage collagens types II, IX and XI to degradation by the cysteine proteinases, cathepsins B and L. FEBS Lett 1990,269:189-193.
74. Sieper J. Treatment challenges in axial spondylarthritis and future directions. Curr Rheumatol Rep 2013,15:356.
75. Reveille JD. Genetics of spondyloarthritis--beyond the MHC. Nat Rev Rheumatol 2012,8:296-304.
76. Rudwaleit M, Siegert S, Yin Z, Eick J, Thiel A, Radbruch A, et al. Low T cell production of TNFalpha and IFNgamma in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Ann Rheum Dis 2001,60:36-42.
77. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995,38:499-505.
78. Braun J, Yin Z, Spiller I, Siegert S, Rudwaleit M, Liu L, et al. Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. Arthritis Rheum 1999,42:2039-2044.
79. Edwards CK, 3rd, Bendele AM, Reznikov LI, Fantuzzi G, Chlipala ES, Li L, et al.
Soluble human p55 and p75 tumor necrosis factor receptors reverse spontaneous arthritis in transgenic mice expressing transmembrane tumor necrosis factor alpha.
Arthritis Rheum 2006,54:2872-2885.
80. Chang SH, Reynolds JM, Pappu BP, Chen G, Martinez GJ, Dong C. Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E.
Immunity 2011,35:611-621.
81. Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system.
Nat Rev Immunol 2010,10:479-489.
82. Lin AM, Rubin CJ, Khandpur R, Wang JY, Riblett M, Yalavarthi S, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 2011,187:490-500.
83. Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009,9:556-567.
84. Chang SH, Park H, Dong C. Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. J Biol Chem 2006,281:35603-35607.
85. Francois RJ, Gardner DL, Degrave EJ, Bywaters EG. Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis. Arthritis Rheum 2000,43:2011-2024.
86. Bollow M, Fischer T, Reisshauer H, Backhaus M, Sieper J, Hamm B, et al.
Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis- cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 2000,59:135-140.
87. Muche B, Bollow M, Francois RJ, Sieper J, Hamm B, Braun J. Anatomic structures involved in early- and late-stage sacroiliitis in spondylarthritis: a detailed analysis by contrast-enhanced magnetic resonance imaging. Arthritis Rheum 2003,48:1374-1384.
5 Literaturverzeichnis
88. Gong Y, Zheng N, Chen SB, Xiao ZY, Wu MY, Liu Y, et al. Ten years' experience with needle biopsy in the early diagnosis of sacroiliitis. Arthritis Rheum 2012,64:1399-1406.
89. Cruickshank B. Histopathology of diarthrodial joints in ankylosing spondylitis. Ann Rheum Dis 1951,10:393-404.
90. Cruickshank B. Lesions of cartilaginous joints in ankylosing spondylitis. J Pathol Bacteriol 1956,71:73-84.
91. Clinicopathological conference. A case of early ankylosing spondylitis with fatal secondary amyloidosis. Br Med J 1968,2:412-416.
92. Aufdermaur M. Pathogenesis of square bodies in ankylosing spondylitis. Ann Rheum Dis 1989,48:628-631.
93. de Vlam K, Mielants H, Veys EM. Involvement of the zygapophyseal joint in ankylosing spondylitis: relation to the bridging syndesmophyte. J Rheumatol 1999,26:1738-1745.
94. Glover JR. Arthrography of the joints of the lumbar vertebral arches. Orthop Clin North Am 1977,8:37-42.
95. Xu GL, Haughton VM, Carrera GF. Lumbar facet joint capsule: appearance at MR imaging and CT. Radiology 1990,177:415-420.
96. Beaman DN, Graziano GP, Glover RA, Wojtys EM, Chang V. Substance P innervation of lumbar spine facet joints. Spine (Phila Pa 1976) 1993,18:1044-1049.
97. Edgar MA, Ghadially JA. Innervation of the lumbar spine. Clin Orthop Relat Res 1976:35-41.
98. Jaumard NV, Welch WC, Winkelstein BA. Spinal facet joint biomechanics and mechanotransduction in normal, injury and degenerative conditions. J Biomech Eng 2011,133:071010.
99. Masharawi Y, Rothschild B, Dar G, Peleg S, Robinson D, Been E, et al. Facet orientation in the thoracolumbar spine: three-dimensional anatomic and biomechanical analysis. Spine (Phila Pa 1976) 2004,29:1755-1763.
100. Appel H, Kuhne M, Spiekermann S, Ebhardt H, Grozdanovic Z, Kohler D, et al.
Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum 2006,54:2845-2851.
101. Benjamin M, McGonagle D. Entheses: tendon and ligament attachment sites. Scand J Med Sci Sports 2009,19:520-527.
102. Laloux L, Voisin MC, Allain J, Martin N, Kerboull L, Chevalier X, et al.
Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 2001,60:316-321.
103. Ball J. Enthesopathy of rheumatoid and ankylosing spondylitis. Ann Rheum Dis 1971,30:213-223.
104. Holtzer H. Control of Chondrogenesis in the Embryo. Biophys J 1964,4:SUPPL239-255.
105. Hall BK, Miyake T. All for one and one for all: condensations and the initiation of skeletal development. Bioessays 2000,22:138-147.
106. Huang W, Chung UI, Kronenberg HM, de Crombrugghe B. The chondrogenic transcription factor Sox9 is a target of signaling by the parathyroid hormone-related peptide in the growth plate of endochondral bones. Proc Natl Acad Sci U S A 2001,98:160-165.
107. Noonan KJ, Hunziker EB, Nessler J, Buckwalter JA. Changes in cell, matrix compartment, and fibrillar collagen volumes between growth-plate zones. J Orthop Res 1998,16:500-508.
5 Literaturverzeichnis
108. Studer D, Millan C, Ozturk E, Maniura-Weber K, Zenobi-Wong M. Molecular and biophysical mechanisms regulating hypertrophic differentiation in chondrocytes and mesenchymal stem cells. Eur Cell Mater 2012,24:118-135; discussion 135.
109. Stricker S, Fundele R, Vortkamp A, Mundlos S. Role of Runx genes in chondrocyte differentiation. Dev Biol 2002,245:95-108.
110. Stickens D, Behonick DJ, Ortega N, Heyer B, Hartenstein B, Yu Y, et al. Altered endochondral bone development in matrix metalloproteinase 13-deficient mice.
Development 2004,131:5883-5895.
111. Shen G. The role of type X collagen in facilitating and regulating endochondral ossification of articular cartilage. Orthod Craniofac Res 2005,8:11-17.
112. Wuelling M, Vortkamp A. Chondrocyte proliferation and differentiation. Endocr Dev 2011,21:1-11.
113. Karsenty G. Transcriptional control of skeletogenesis. Annu Rev Genomics Hum Genet 2008,9:183-196.
114. Han Y, Lefebvre V. L-Sox5 and Sox6 drive expression of the aggrecan gene in cartilage by securing binding of Sox9 to a far-upstream enhancer. Mol Cell Biol 2008,28:4999-5013.
115. Moskalewski S, Hyc A, Jankowska-Steifer E, Osiecka-Iwan A. Formation of synovial joints and articular cartilage. Folia Morphol (Warsz) 2013,72:181-187.
116. Holder N. An experimental investigation into the early development of the chick elbow joint. J Embryol Exp Morphol 1977,39:115-127.
117. Umlauf D, Frank S, Pap T, Bertrand J. Cartilage biology, pathology, and repair. Cell Mol Life Sci 2010,67:4197-4211.
118. Wong M, Carter DR. Articular cartilage functional histomorphology and mechanobiology: a research perspective. Bone 2003,33:1-13.
119. Fawns HT, Landells JW. Histochemical studies of rheumatic conditions. I.
Observations on the fine structures of the matrix of normal bone and cartilage. Ann Rheum Dis 1953,12:105-113.
120. Lane LB, Villacin A, Bullough PG. The vascularity and remodelling of subchondrial bone and calcified cartilage in adult human femoral and humeral heads. An age- and stress-related phenomenon. J Bone Joint Surg Br 1977,59:272-278.
121. Poole AR, Kojima T, Yasuda T, Mwale F, Kobayashi M, Laverty S. Composition and structure of articular cartilage: a template for tissue repair. Clin Orthop Relat Res 2001:S26-33.
122. Strobel S, Loparic M, Wendt D, Schenk AD, Candrian C, Lindberg RL, et al.
Anabolic and catabolic responses of human articular chondrocytes to varying oxygen percentages. Arthritis Res Ther 2010,12:R34.
123. Cernanec J, Guilak F, Weinberg JB, Pisetsky DS, Fermor B. Influence of hypoxia and reoxygenation on cytokine-induced production of proinflammatory mediators in articular cartilage. Arthritis Rheum 2002,46:968-975.
124. Greene GW, Banquy X, Lee DW, Lowrey DD, Yu J, Israelachvili JN. Adaptive mechanically controlled lubrication mechanism found in articular joints. Proc Natl Acad Sci U S A 2011,108:5255-5259.
125. O'Hara BP, Urban JP, Maroudas A. Influence of cyclic loading on the nutrition of articular cartilage. Ann Rheum Dis 1990,49:536-539.
126. Maksymowych WP. Progress in spondylarthritis. Spondyloarthritis: lessons from imaging. Arthritis Res Ther 2009,11:222.
127. Sieper J, Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, et al. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology (Oxford) 2005,44:1525-1530.
5 Literaturverzeichnis
128. Maksymowych WP, Chiowchanwisawakit P, Clare T, Pedersen SJ, Ostergaard M, Lambert RG. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum 2009,60:93-102.
129. Maksymowych WP. Disease modification in ankylosing spondylitis. Nat Rev Rheumatol 2010,6:75-81.
130. van der Heijde D, Landewe R, Baraliakos X, Houben H, van Tubergen A, Williamson P, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008,58:3063-3070.
131. van der Heijde D, Landewe R, Einstein S, Ory P, Vosse D, Ni L, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008,58:1324-1331.
132. van der Heijde D, Salonen D, Weissman BN, Landewe R, Maksymowych WP, Kupper H, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009,11:R127.
133. Lories RJ, Luyten FP, de Vlam K. Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis. Arthritis Res Ther 2009,11:221.
134. Lories RJ, Derese I, de Bari C, Luyten FP. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum 2007,56:489-497.
135. Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 2005,115:1571-1579.
136. Hreggvidsdottir HS, Noordenbos T, Baeten DL. Inflammatory pathways in spondyloarthritis. Mol Immunol 2014,57:28-37.
137. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis 2005,64:1462-1466.
138. Schett G, Landewe R, van der Heijde D. Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction?
Ann Rheum Dis 2007,66:709-711.
139. Wanders A, Heijde D, Landewe R, Behier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005,52:1756-1765.
140. Zhang X, Schwarz EM, Young DA, Puzas JE, Rosier RN, O'Keefe RJ.
Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 2002,109:1405-1415.
141. Bennett AN, Rehman A, Hensor EM, Marzo-Ortega H, Emery P, McGonagle D. The fatty Romanus lesion: a non-inflammatory spinal MRI lesion specific for axial spondyloarthropathy. Ann Rheum Dis 2010,69:891-894.
142. Del Fattore A, Teti A, Rucci N. Bone cells and the mechanisms of bone remodelling.
Front Biosci (Elite Ed) 2012,4:2302-2321.
143. Ball J. Symposium on the Spondylarthritides. Aspects of pathology. Rheumatol Rehabil 1979,18:210-213.
144. Lories R. The balance of tissue repair and remodeling in chronic arthritis. Nat Rev Rheumatol 2011,7:700-707.
145. Urist MR. Bone: formation by autoinduction. Science 1965,150:893-899.
5 Literaturverzeichnis
146. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, et al. Novel regulators of bone formation: molecular clones and activities. Science 1988,242:1528-1534.
147. Lefebvre V, Bhattaram P. Vertebrate skeletogenesis. Curr Top Dev Biol 2010,90:291-317.
148. Day TF, Guo X, Garrett-Beal L, Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 2005,8:739-750.
149. Yuasa T, Otani T, Koike T, Iwamoto M, Enomoto-Iwamoto M. Wnt/beta-catenin signaling stimulates matrix catabolic genes and activity in articular chondrocytes: its possible role in joint degeneration. Lab Invest 2008,88:264-274.
150. Guo X, Day TF, Jiang X, Garrett-Beal L, Topol L, Yang Y. Wnt/beta-catenin signaling is sufficient and necessary for synovial joint formation. Genes Dev 2004,18:2404-2417.
151. Zhu M, Tang D, Wu Q, Hao S, Chen M, Xie C, et al. Activation of beta-catenin signaling in articular chondrocytes leads to osteoarthritis-like phenotype in adult beta-catenin conditional activation mice. J Bone Miner Res 2009,24:12-21.
152. Luyten FP, Tylzanowski P, Lories RJ. Wnt signaling and osteoarthritis. Bone 2009,44:522-527.
153. Lories RJ, Peeters J, Bakker A, Tylzanowski P, Derese I, Schrooten J, et al. Articular cartilage and biomechanical properties of the long bones in Frzb-knockout mice.
Arthritis Rheum 2007,56:4095-4103.
154. Mackie EJ, Tatarczuch L, Mirams M. The skeleton: a multi-functional complex organ:
the growth plate chondrocyte and endochondral ossification. J Endocrinol 2011,211:109-121.
155. Wenham CY, Grainger AJ, Conaghan PG. The role of imaging modalities in the diagnosis, differential diagnosis and clinical assessment of peripheral joint osteoarthritis. Osteoarthritis Cartilage 2014,22:1692-1702.
156. Karsdal MA, Bay-Jensen AC, Lories RJ, Abramson S, Spector T, Pastoureau P, et al.
The coupling of bone and cartilage turnover in osteoarthritis: opportunities for bone antiresorptives and anabolics as potential treatments? Ann Rheum Dis 2014,73:336-348.
157. Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum 2012,64:1697-1707.
158. Goldring MB, Goldring SR. Osteoarthritis. J Cell Physiol 2007,213:626-634.
159. van der Kraan PM, van den Berg WB. Osteophytes: relevance and biology.
Osteoarthritis Cartilage 2007,15:237-244.
160. Felson DT. Clinical practice. Osteoarthritis of the knee. N Engl J Med 2006,354:841-848.
161. Blagojevic M, Jinks C, Jeffery A, Jordan KP. Risk factors for onset of osteoarthritis of the knee in older adults: a systematic review and meta-analysis. Osteoarthritis Cartilage 2010,18:24-33.
162. Wieland HA, Michaelis M, Kirschbaum BJ, Rudolphi KA. Osteoarthritis - an untreatable disease? Nat Rev Drug Discov 2005,4:331-344.
163. Bruyere O, Cooper C, Pelletier JP, Branco J, Luisa Brandi M, Guillemin F, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum 2014.
164. van den Berg WB. Lessons from animal models of arthritis over the past decade.
Arthritis Res Ther 2009,11:250.